Background: CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
Description: PE-conjugated Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
Storage & Shipping: Store at 2°C-8°C for 6 months
Formulation & Reconstitution: Liquid，PBS with 0.05% Proclin300, 355% BSA
Target: CL2A
Uniprot ID: N.A.
Usage: Research use only
Clone ID: 1G9
Purification: Purified from cell culture supernatant by affinity chromatography
Recommended Dilutions: Flow Cyt 1:100
English
Deutsch
